Abstract
We describe the development and validation of a novel 3D-printed nasopharyngeal swab for the identification of SARS-CoV-2. We subjected the novel swab to mechanical and fluid absorption testing ex-vivo, and confirmed its ability to retain and release murine coronavirus and SARS-CoV-2. Compared to the Copan FLOQSwab, the novel swab displayed excellent correlation of RT-PCR cycle threshold values on paired clinical testing in COVID-19 patients, at r = 0.918 and 0.943 for the SARS-CoV-2 ORF1/a and sarbecovirus E-gene respectively. Overall positive and negative percent agreement was 90.6% and 100% respectively on a dual-assay RT-PCR platform, with discordant samples observed only at high cycle thresholds. When carefully designed and tested, 3D-printed swabs are a viable alternative to traditional swabs and will help mitigate strained resources in the escalating COVID-19 pandemic.
Competing Interest Statement
The National University of Singapore is in the process of licensing out fabrication of nasopharyngeal swabs to commercial entities, based on the Python swab described here and has filed for patent protection, together with CCY and WTEC. All clinical aspects of the study (clinical testing, analysis and interpretation) were performed independently from the swab design team, including CCY and WTEC.
Funding Statement
This study was supported in part by the National Medical Research Council, Singapore (Grant: NMRC/CIRG18nov-0045) and the National Research Foundation, Singapore under its International Research Centres in Singapore Funding Initiative. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of National Medical Research Council or the National Research Foundation, Singapore. The funding sources were not involved in the data collection, analysis or interpretation, or any aspect pertinent to the conclusions of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the National Healthcare Group, Singapore (Approval number: DSRB 2020/00464)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data shown in the manuscript is available upon request from the corresponding author. The source code to reproduce the clinical statistical analysis is made available at https://github.com/josh-tay/COVID-19_Python_swab.